Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Aeras and Crucell Announce Start of a Tuberculosis Vaccine Clinical Trial in the United States. Aeras commits a further USD 5 million to the development of the tuberculosis vaccine
- Leiden, The Netherlands, December 21, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it will receive up to USD 5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation to support the...
- Research articles 2007-12-21
- Crucell, AERAS and SATVI Announce Start of Tuberculosis Vaccine Clinical Trial in South Africa six months after launching initial trial in the United States
- Leiden, The Netherlands, May 11, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX), the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative SATVI at the University of Cape Town today...
- Research articles 2007-05-11
- Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial
- Leiden, The Netherlands, October 25, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has started the phase I clinical trial of the AdVac®-based tuberculosis vaccine it is developing in...
- Research articles 2006-10-25
Additional Resources
- Aeras and Vanderbilt University Announce License Deal for New Tuberculosis Vaccine.
- Byline: Vanderbilt Medical Center NASHVILLE, Tenn., May 4 AScribe Newswire -- The Aeras Global TB Vaccine Foundation of Bethesda, Md., and Vanderbilt University of Nashville, Tenn., announced today that the two organizations had executed an exclusive license for a tuberculosis vaccine based on ...
- Research articles 2006-05-04
- Aeras commits further USD$5 million to existing TB research agreement with Crucell
- PRESS RELEASE Aeras commits further USD$5 million to existing TB research agreement with Crucell Leiden, The Netherlands, March 7, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced it will receive up to USD$5 million from Rockville, Maryland-headquartered Aeras Global TB Vaccine Foundation...
- Research articles 2007-03-07
- Crucell/Aeras Start Turberculosis Vaccine Clinical Trial
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) has started the phase I clinical trial of the AdVac-based tuberculosis vaccine it is developing in partnership with The AERAS Global TB Vaccine Foundation. The clinical trial will be an open-label study that will test the vaccine in...
- Research articles 2006-12-01
- Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
- Atlanta, Georgia, USA / Leiden, The Netherlands, 9 April 2008 - Dutch biotechnology company Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative SATVI present a progress update and immunology data from a...
- Research articles 2008-04-09
- The Netherlands Invest EUR 18.4 Million to Develop Better Vaccines to Fight Raging TB Pandemic
- Aeras to Partner with Crucell, KNCV Tuberculosis Foundation and other Top Dutch Scientific Organisations (The Netherlands, Nov. 3, 2006) As extreme forms of drug resistant tuberculosis threaten to make the TB pandemic even worse, Dutch funding and scientific expertise are playing a critical role in the development of new,...
- Research articles 2006-11-03
- Crucell receives $5 million for TB vaccine development
- INVESTMENTCrucell NV the Netherlands is to receive up to $5 million from Aeras Global TB vaccine Foundation US to support the advanced development of the candidate AdVac-based tuberculosis vaccine."This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important...
- Research articles 2007-05-01
- << Previous
- page 1 of 1
- Next >>
